Automated immunochemistry instruments are expected to witness robust growth in India owing to increasing government focus toward healthcare infrastructure development, rising number of pathology laboratories, and growing number of private and public hospitals.
Five companies in India dominate this segment at a combined 72.5 percent share, with CLIA, at the expense of ELISA and rapid tests, steadily gaining share.
The market is increasingly seeing the entry of chemiluminescence immunoassay systems, with smaller labs opting for semi-automated CLIAs or FIAs, though in the short term, ELSA systems are also exhibiting growth.
Under strong rules and regulations, laboratories are finding it difficult to have good revenues. It is imperative to find ways to sustain a unit in such a cost-crunched environment.
The immunochemistry market will face increasing competition from other diagnostic technologies and so future growth will depend on the availability of more clinical evidence to prove effectiveness of immunochemistry tests.
With intense R&D currently being carried out by small and major companies, the future looks bright for this segment.
The current trend is moving toward multi-parametric assays, with an upsurge in multiplex technologies using protein and peptide arrays for autoimmune diagnostics.